Ads
related to: anti pdl1 drug list- Unresectable HCC Therapy
Combination Treatment For
Unresectable HCC. Visit Site.
- Clinical Study Data
View Data For An Unresectable
Hepatocellular Carcinoma Treatment.
- Safety Info From A Study
See Adverse Reaction Data For A
First-Line Unresectable HCC Therapy
- Official Oncologist Site
Visit Official HCP Site To Learn
About An Immunotherapy Option.
- View The Dosing Regimen
See The Dosing Schedule For A
Unresectable HCC Treatment
- Mechanism Of Action Info
Is Combination Treatment An Option
For Your Unresectable HCC Patients?
- Unresectable HCC Therapy
Search results
Results From The WOW.Com Content Network
Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent and Eli Lilly for patients with non-small cell lung cancer . [27] Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody in pivotal Phase 3 and Phase 2 clinical trials in solid tumors and hematologic cancers. [28]
Anti-CD20 antibody which is tagged with I131. Non-Hodgkin's lymphoma: Grade 3-4 cytopenias, methaemoglobinaemia, acute myeloid leukaemia or myelodysplastic syndrome, anaphylaxis and hyperthyroidism. Trastuzumab: IV: Anti-HER2 antibody. HER2-positive breast cancer, gastric cancer, pancreatic cancer (orphan) and gastro-oesophageal junction cancer.
This page was last edited on 9 February 2024, at 00:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The first checkpoint antibody approved by the FDA was ipilimumab, approved in 2011 for treatment of melanoma. [2] It blocks the immune checkpoint molecule CTLA-4.Clinical trials have also shown some benefits of anti-CTLA-4 therapy on lung cancer or pancreatic cancer, specifically in combination with other drugs.
Sugemalimab is a fully human monoclonal antibody that targets the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and possesses immune checkpoint inhibitory and antineoplastic properties. [10]
Ligand for PD1 (CD279) and also CD80 (B7-1). Formation of PD1/PDL1 or B7-1/PDL1 complexes transmit an inhibitory signal reducing proliferation of CD8+ T cells at lymph nodes. Anti-PDL1 drugs like Atezolizumab, currently in trials for bladder cancer, work by preventing the inhibition of T-cells. CD275: ICOS-L (ICOS ligand)
Ads
related to: anti pdl1 drug list